Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LixiLan-G: Insulin Glargine/Lixisenatide FRC vs GLP-1 RA in T2DM
NCT02787551Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2016
- Primary completion
- May 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoints: Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26 and Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 52. Started Jul 2016; status: completed.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02787551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02787551.